您的位置：首页>>分析化学>>脂类分析标准品>>H1514 神经酰胺三己糖苷 Ceramide trihexosides (bottom spot)

产品中心

/ Products Classification 点击展开+

生命科学

分析化学

糖科学

生化试剂

仪器耗材

Cat. Number
H1514
Chemical Name
H1514 神经酰胺三己糖苷 Ceramide trihexosides (bottom spot)
Category
natural
Mol. Formula
C54H101NO19
Mol. Weight
1068
Qty 1
0.5mg
Appearance
solid
Application Notes
98+% TLC
Synonym
CTH with hydroxy fatty acid side chain
Solubility
hot methanol, DMSO, chloroform/methanol, 1:1
Storage condition
-20°C
References

1. S. Ashkenazi and T. G. Cleary, “Rapid method to detect shiga toxin and shiga-like toxin I based on binding to globotriosyl ceramide (Gb3), their natural receptor.” J Clin Microbio. June; 27(6): 1145-1150, 1989
2. S. Bekri, O. Lidove, R. Jaussaud, B. Knebelmann, F. Barbey. "The role of ceramide trihexoside (globotriaosylceramide) in the diagnosis and follow-up of the efficacy of treatment of Fabry disease: a review of the literature". Cardiovasc Hematol Agents Med Chem 4 (4): 289–97, October 2006
3. J. E. Groener, B. J. Poorthuis, S. Kuiper, M. T. Helmond, C. E. Hollak, J. M. Aerts. “HPLC for simultaneous quantification of total ceramide, glucosylceramide, and ceramide trihexoside concentrations in plasma.” Clin Chem., Apr;53(4):742-7, 2007. Epub Mar 1 2007
4. K. Mills, A. Johnson, B. Winchester. “Synthesis of novel internal standards for the quantitative determination of plasma ceramide trihexoside in Fabry disease by tandem mass spectrometry.” FEBS Lett., Mar 27;515(1-3):171-6, 2002
5. C. Menge, I. Stamm, M. Wuhrer, R. Geyer, L. H. Wieler, G. Baljer. “Globotriaosylceramide (Gb(3)/CD77) is synthesized and surface expressed by bovine lymphocytes upon activation in vitro.” Vet Immunol Immunopathol., Nov;83(1-2):19-36, 2001
下一个：Ceramide trihexosides (top spot)上一个：抗神经节苷脂GM4多克隆抗体 Anti-ganglioside GM4(polyclonal antibody)
联系我们
  • 电话：021-60498804
  • 邮箱：info@e-biochem.com
  • 地址：上海市徐汇区漕溪路258弄27号航星商务楼2-404
扫一扫，关注我们
惠诚品牌
产品中心
分子生物
分析化学
生化试剂
仪器耗材
企业动态
技术资料
Copyright © 2022 上海惠诚生物科技有限公司   沪ICP备2021037845号-6  
在线咨询 联系方式 二维码

服务热线

021-60498804

扫一扫，关注我们